Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-nr4z6 Total loading time: 0 Render date: 2024-05-17T01:22:19.124Z Has data issue: false hasContentIssue false

Chapter 24 - Cerebrospinal fluid and blood biomarkers as outcome measures in clinical trials for Parkinson's disease

from Section IV - Clinical Trials in Parkinson's Diease: Lessons, Controversies and Challenges

Published online by Cambridge University Press:  05 March 2016

By
Thomas F. Tropea  and
Claire Henchcliffe
Edited by
Néstor Gálvez-Jiménez ,
Hubert H. Fernandez ,
Alberto J. Espay  and
Susan H. Fox
Néstor Gálvez-Jiménez
Affiliation:
Cleveland Clinic, Florida
Hubert H. Fernandez
Affiliation:
Cleveland Clinic, Ohio
Alberto J. Espay
Affiliation:
University of Cincinnati
Susan H. Fox
Affiliation:
Toronto Western Hospital
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Parkinson's Disease
Current and Future Therapeutics and Clinical Trials
 , pp. 249 - 264
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89–95.Google Scholar
Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287: 1653–61.Google Scholar
Whone, AL, Watts, RL, Stoessl, AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54: 93–101.Google Scholar
Fahn, S, Oakes, D, Shoulson, I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498–508.Google Scholar
Freed, CR, Greene, PE, Breeze, RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344: 710–19.Google Scholar
Olanow, CW, Goetz, CG, Kordower, JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003; 54: 403–14.CrossRefGoogle ScholarPubMed
Feigin, A, Kaplitt, MG, Tang, C, et al. Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci U S A 2007; 104: 19559–64.Google Scholar
Parkinson Progression Marker Initiative. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011; 95: 629–35.CrossRefGoogle Scholar
Kang, UJ, Alcalay, R, Goldman, JG, et al. The BioFIND study (Fox Investigation for New Discovery of Biomarkers in Parkinson's disease): design and methodology. Neurology 2014; 10 (Suppl.): P4.043.Google Scholar
Parkinson Study Group. DATATOP: a decade of neuroprotective inquiry. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism. Ann Neurol 1998; 44: S160–6.Google Scholar
Gerlach, M, Maetzler, W, Broich, K, et al. Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. J Neural Transm 2012; 119: 39–52.CrossRefGoogle ScholarPubMed
Michell, AW, Lewis, SJ, Foltynie, T, Barker, RA. Biomarkers and Parkinson's disease. Brain 2004; 127: 1693–705.Google Scholar
LeWitt, P. Recent advances in CSF biomarkers for Parkinson's disease. Parkinsonism Relat Disord 2012; 18 (Suppl. 1): S49–51.Google Scholar
LeWitt, P, Schultz, L, Auinger, P, et al. CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease. Brain Res 2011; 1408: 88–97.Google Scholar
Zhou, G, Miura, Y, Shoji, H, Yamada, S, Matsuishi, T. Platelet monoamine oxidase B and plasma β-phenylethylamine in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001; 70: 229–31.Google Scholar
Barbanti, P, Fabbrini, G, Ricci, A, et al. Increased expression of dopamine receptors on lymphocytes in Parkinson's disease. Mov Disord 1999; 14: 764–71.Google Scholar
Gui, YX, Wan, Y, Xiao, Q, et al. Verification of expressions of Kir2 as potential peripheral biomarkers in lymphocytes from patients with Parkinson's disease. Neurosci Lett 2011; 505: 104–8.CrossRefGoogle ScholarPubMed
Iwanaga, K, Wakabayashi, K, Yoshimoto, M, et al. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology 1999; 52: 1269–71.Google Scholar
Minguez-Castellanos, A, Chamorro, CE, Escamilla-Sevilla, F, et al. Do α-synuclein aggregates in autonomic plexuses predate Lewy body disorders? A cohort study. Neurology 2007; 68: 2012–18.Google Scholar
Beach, TG, Adler, CH, Dugger, BN, et al. Submandibular gland biopsy for the diagnosis of Parkinson disease. J Neuropathol Exp Neurol 2013; 72: 130–6.Google Scholar
Wang, N, Gibbons, CH, Lafo, J, et al. α-Synuclein in cutaneous autonomic nerves. Neurology 2013; 81: 1604–10.Google Scholar
El-Agnaf, OM, Salem, SA, Paleologou, KE, et al. Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. Faseb J 2006; 20: 419–25.Google Scholar
Tinsley, RB, Kotschet, K, Modesto, D, et al. Sensitive and specific detection of α-synuclein in human plasma. J Neurosci Res 2010; 88: 2693–700.Google Scholar
Foulds, PG, Mitchell, JD, Parker, A, et al. Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J 2011; 25: 4127–37.Google Scholar
Tokuda, T, Salem, SA, Allsop, D, et al. Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 2006; 349: 162–6.Google Scholar
Lee, PH, Lee, G, Park, HJ, et al. The plasma α-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J Neural Transm 2006; 113: 1435–9.Google Scholar
Shi, M, Zabetian, CP, Hancock, AM, et al. Significance and confounders of peripheral DJ-1 and α-synuclein in Parkinson's disease. Neuroscience Lett 2010; 480: 78–82.CrossRefGoogle ScholarPubMed
Li, QX, Mok, SS, Laughton, KM, et al. Plasma α-synuclein is decreased in subjects with Parkinson's disease. Exp Neurol 2007; 204: 583–8.Google Scholar
Ohrfelt, A, Grognet, P, Andreasen, N, et al. Cerebrospinal fluid α-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett 2009; 450: 332–5.Google Scholar
Hong, Z, Shi, M, Chung, K, et al. DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010; 133: 713–26.Google Scholar
Waragai, M, Sekiyama, K, Sekigawa, A, et al. α-Synuclein and DJ-1 as potential biological fluid biomarkers for Parkinson's Disease. Int J Mol Sci 2010; 11: 4257–66.Google Scholar
Mollenhauer, B, Locascio, JJ, Schulz-Schaeffer, W, et al. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011; 10: 230–40.Google Scholar
Wennstrom, M, Surova, Y, Hall, S, et al. Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One 2013; 8: e53250.Google Scholar
Hall, S, Ohrfelt, A, Constantinescu, R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012; 69: 1445–52.Google Scholar
Kang, JH, Irwin, DJ, Chen-Plotkin, AS, et al. Association of cerebrospinal fluid beta-amyloid 1–42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 2013; 70: 1277–87.Google Scholar
Mollenhauer, B, Trautmann, E, Taylor, P, et al. Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci Lett 2013; 532: 44–8.Google Scholar
Shi, M, Bradner, J, Hancock, AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011; 69: 570–80.CrossRefGoogle ScholarPubMed
Stewart, T, Liu, C, Ginghina, C, et al. Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol 2014; 184: 966–75.Google Scholar
Masliah, E, Rockenstein, E, Adame, A, et al. Effects of α-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005; 46: 857–68.Google Scholar
Masliah, E, Rockenstein, E, Mante, M, et al. Passive immunization reduces behavioral and neuropathological deficits in an α-synuclein transgenic model of Lewy body disease. PLoS One 2011; 6: e19338.Google Scholar
Nasstrom, T, Goncalves, S, Sahlin, C, et al. Antibodies against α-synuclein reduce oligomerization in living cells. PLoS One 2011; 6: e27230.Google Scholar
Blennow, K, Zetterberg, H, Rinne, JO, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 2012; 69: 1002–10.Google Scholar
Salloway, S, Sperling, R, Fox, NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014; 370: 322–33.Google Scholar
Farlow, M, Arnold, SE, van Dyck, CH, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement 2012; 8: 261–71.Google Scholar
Doody, RS, Thomas, RG, Farlow, M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014; 370: 311–21.Google Scholar
Maita, C, Tsuji, S, Yabe, I, et al. Secretion of DJ-1 into the serum of patients with Parkinson's disease. Neurosci Lett 2008; 431: 86–9.Google Scholar
Waragai, M, Nakai, M, Wei, J, et al. Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease. Neurosci Lett 2007; 425: 18–22.CrossRefGoogle ScholarPubMed
Waragai, M, Wei, J, Fujita, M, et al. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun 2006; 345: 967–72.Google Scholar
Lin, X, Cook, TJ, Zabetian, CP, et al. DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. Sci Rep 2012; 2: 954.Google Scholar
Saito, Y, Hamakubo, T, Yoshida, Y, et al. Preparation and application of monoclonal antibodies against oxidized DJ-1. Significant elevation of oxidized DJ-1 in erythrocytes of early-stage Parkinson disease patients. Neurosci Lett 2009; 465: 1–5.Google Scholar
Rosén, C, Hansson, O, Blennow, K, Zetterberg, H. Fluid biomarkers in Alzheimer's disease – current concepts. Mol Neurodegener 2013; 8: 20–31.Google Scholar
Maarouf, CL, Beach, TG, Adler, CH, et al. Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology. Biomark Insights 2013; 8: 19–28.Google Scholar
Siderowf, A, Xie, SX, Hurtig, H, et al. CSF amyloid β1–42 predicts cognitive decline in Parkinson disease. Neurology 2010; 75: 1055–61.Google Scholar
Wang, Y, Hancock, AM, Bradner, J, et al. Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Am J Pathol 2011; 178: 1509–16.Google Scholar
Leverenz, JB, Watson, GS, Shofer, J, et al. Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. Parkinsonism Relat Disord 2011; 17: 61–4.Google Scholar
Henchcliffe, C, Beal, MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 2008; 4: 600–9.Google Scholar
Hauser, DN, Hastings, TG. Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiol Dis 2013; 51: 35–42.CrossRefGoogle ScholarPubMed
Younes-Mhenni, S, Frih-Ayed, M, Kerkeni, A, Bost, M, Chazot, G. Peripheral blood markers of oxidative stress in Parkinson's disease. Eur Neurol 2007; 58: 78–83.Google Scholar
Götz, ME, Gerstner, A, Harth, R, et al. Altered redox state of platelet coenzyme Q10 in Parkinson's disease. J Neural Transm 2000; 107: 41–8.Google ScholarPubMed
Sohmiya, M, Tanaka, M, Tak, NW, et al. Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease. J Neurol Sci 2004; 223: 161–6.Google Scholar
Isobe, C, Abe, T, Terayama, Y. Levels of reduced and oxidized coenzymeQ-10 and 8-hydroxy-2'-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. Neurosci Lett 2010; 469: 159–63.Google Scholar
Ilic, TV, Jovanovic, M, Jovicic, A, Tomovic, M. Oxidative stress indicators are elevated in de novo Parkinson's disease patients. Funct Neurol 1999; 14: 141–7.Google Scholar
Seet, RC, Lee, CY, Lim, EC, et al. Oxidative damage in Parkinson disease: Measurement using accurate biomarkers. Free Radic Biol Med 2010; 48: 560–6.Google Scholar
Bogdanov, M, Matson, WR, Wang, L, et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008; 131: 389–96.Google Scholar
Gmitterova, K, Heinemann, U, Gawinecka, J, et al. 8-OHdG in cerebrospinal fluid as a marker of oxidative stress in various neurodegenerative diseases. Neurodegener Dis 2009; 6: 263–9.Google Scholar
Andreux, PA, Houtkooper, RH, Auwerx, J. Pharmacological approaches to restore mitochondrial function. Nat Rev Drug Discov 2013; 12: 465–83.CrossRefGoogle ScholarPubMed
Seet, RC, Lim, EC, Tan, JJ, et al. Effects of high-dose coenzyme Q10 on biomarkers of oxidative damage and clinical outcomes in Parkinson disease. Antioxidants & Redox Signaling 2014; 21: 211–17.Google Scholar
Cipriani, S, Desjardins, CA, Burdett, TC, et al. Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease. PLoS One 2012; 7: e37331.Google Scholar
Gong, L, Zhang, QL, Zhang, N, et al. Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: linking to Akt/GSK3β signaling pathway. J Neurochem 2012; 123: 876–85.Google Scholar
Chen, X, Burdett, TC, Desjardins, CA, et al. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc Natl Acad Sci U S A 2013; 110: 300–5.Google Scholar
Cipriani, S, Chen, X, Schwarzschild, MA. Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis. Biomark Med 4: 701–12.Google Scholar
Ascherio, A, LeWitt, PA, Xu, K, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009; 66: 1460–8.Google Scholar
Schwarzschild, MA, Schwid, SR, Marek, K, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 2008; 65: 716–23.Google Scholar
The Parkinson Study Group. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol 2014; 71: 141–50.Google Scholar
Johansen, KK, Wang, L, Aasly, JO, et al. Metabolomic profiling in LRRK2-related Parkinson's disease. PLoS One 2009; 4: e7551.Google Scholar
Rentzos, M, Nikolaou, C, Andreadou, E, et al. Circulating interleukin-15 and RANTES chemokine in Parkinson's disease. Acta Neurol Scand 2007; 116: 374–9.Google Scholar
Dufek, M, Hamanova, M, Lokaj, J, et al. Serum inflammatory biomarkers in Parkinson's disease. Parkinsonism Relat Disord 2009; 15: 318–20.CrossRefGoogle ScholarPubMed
Mogi, M, Harada, M, Riederer, P, et al. Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 1994; 165: 208–10.Google Scholar
Barnum, CJ, Tansey, MG. Neuroinflammation and non-motor symptoms: the dark passenger of Parkinson's disease? Curr Neurol Neurosci Rep 2012; 12: 350–8.CrossRefGoogle ScholarPubMed
Rocha, NP, Teixeira, AL, Scalzo, PL, et al. Plasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson's disease. Mov Disord 2014; 29: 527–31.Google Scholar
Lindqvist, D, Hall, S, Surova, Y, et al. Cerebrospinal fluid inflammatory markers in Parkinson's disease – associations with depression, fatigue, and cognitive impairment. Brain Behav Immun 2013; 33: 183–9.Google Scholar
Hisanaga, K, Asagi, M, Itoyama, Y, Iwasaki, Y. Increase in peripheral CD4 bright+ CD8 dull+ T cells in Parkinson disease. Arch Neurol 2001; 58: 1580–3.Google Scholar
Fiszer, U, Mix, E, Fredrikson, S, Kostulas, V, Link, H. Parkinson's disease and immunological abnormalities: increase of HLA-DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood. Acta Neurol Scand 1994; 90: 160–6.Google Scholar
Double, KL, Rowe, DB, Carew-Jones, FM, et al. Anti-melanin antibodies are increased in sera in Parkinson's disease. Exp Neurol 2009; 217: 297–301.Google Scholar
McRae-Degueurce, A, Klawans, HL, Penn, RD, et al. An antibody in the CSF of Parkinson's disease patients disappears following adrenal medulla transplantation. Neurosci Lett 1988; 94: 192–7.Google Scholar
Kaplitt, MG, Feigin, A, Tang, C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007; 369: 2097–105.Google Scholar
Papachroni, KK, Ninkina, N, Papapanagiotou, A, et al. Autoantibodies to α-synuclein in inherited Parkinson's disease. J Neurochem 2007; 101: 749–56.Google Scholar
Yanamandra, K, Gruden, MA, Casaite, V, et al. α-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. PLoS One 2011; 6: e18513.Google Scholar
Caudle, WM, Bammler, TK, Lin, Y, Pan, S, Zhang, J. Using ‘omics’ to define pathogenesis and biomarkers of Parkinson's disease. Expert Rev Neurother 2010; 10: 925–42.CrossRefGoogle ScholarPubMed
Grunblatt, E, Mandel, S, Jacob-Hirsch, J, et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 2004; 111: 1543–73.Google Scholar
Moran, LB, Graeber, MB. Towards a pathway definition of Parkinson's disease: a complex disorder with links to cancer, diabetes and inflammation. Neurogenetics 2008; 9: 1–13.Google Scholar
Sutherland, GT, Matigian, NA, Chalk, AM, et al. A cross-study transcriptional analysis of Parkinson's disease. PLoS One 2009; 4: e4955.CrossRefGoogle ScholarPubMed
Grunblatt, E, Zehetmayer, S, Jacob, CP, et al. Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease. J Neural Transm 2010; 117: 1387–93.Google Scholar
Scherzer, CR, Eklund, AC, Morse, LJ, et al. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A 2007; 104: 955–60.Google Scholar
Molochnikov, L, Rabey, JM, Dobronevsky, E, et al. A molecular signature in blood identifies early Parkinson's disease. Mol Neurodegener 2012; 7: 26.Google Scholar
Lauterbach, EC. Psychotropic drug effects on gene transcriptomics relevant to Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 2012; 38: 107–15.Google Scholar
Basso, M, Giraudo, S, Corpillo, D, et al. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 2004; 4: 3943–52.Google Scholar
Werner, CJ, Heyny-von Haussen, R, Mall, G, Wolf, S. Proteome analysis of human substantia nigra in Parkinson's disease. Proteome Science 2008; 6: 8–22.Google Scholar
Abdi, F, Quinn, JF, Jankovic, J, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 2006; 9: 293–348.Google Scholar
Jin, J, Hulette, C, Wang, Y, et al. Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease. Mol Cell Proteomics 2006; 5: 1193–204.Google Scholar
Pan, S, Rush, J, Peskind, ER, et al. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J Proteome Res 2008; 7: 720–30.Google Scholar
Li, YH, Wang, J, Zheng, XL, et al. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry combined with magnetic beads for detecting serum protein biomarkers in parkinson's disease. Eur Neurol 2011; 65: 105–11.Google Scholar
Zhao, X, Xiao, WZ, Pu, XP, et al. Proteome analysis of the sera from Chinese Parkinson's disease patients. Neurosci Lett 2010; 479: 175–9.Google Scholar
Mila, S, Albo, AG, Corpillo, D, et al. Lymphocyte proteomics of Parkinson's disease patients reveals cytoskeletal protein dysregulation and oxidative stress. Biomark Med 2009; 3: 117–28.Google Scholar
Wang, ES, Yao, HB, Chen, YH, et al. Proteomic analysis of the cerebrospinal fluid of Parkinson's disease patients pre- and post-deep brain stimulation. Cell Physiol Biochem 2013; 31: 625–37.Google Scholar
Gershon, RC, Cella, D, Fox, NA, et al. Assessment of neurological and behavioural function: the NIH Toolbox. Lancet Neurolo 2010; 9: 138–9.Google Scholar
Kozauer, N, Katz, R. Regulatory innovation and drug development for early-stage Alzheimer's disease. New Engl J Med 2013; 368: 1169–71.Google Scholar
Vellas, B, Carrillo, MC, Sampaio, C, et al. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement 2013; 9: 438–44.Google Scholar
Mattsson, N, Andreasson, U, Persson, S, et al. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement 2013; 9: 251–61.Google Scholar
Carrillo, MC, Blennow, K, Soares, H, et al. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimers Dement 2013; 9: 137–40.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×